Skip to main content
Mijn bibliotheek
Ga naar:
Nieuws Boeken Tijdschriften Toetsvragen Web-tv Video Audio
Tips voor Mijn BSL
BSL Shop
Inloggen

Welkom bij Erasmus MC & Bohn Stafleu van Loghum

Erasmus MC heeft ervoor gezorgd dat je Mijn BSL eenvoudig en snel kunt raadplegen. Je kunt je links eenvoudig registreren. Met deze gegevens kun je thuis, of waar ook ter wereld toegang krijgen tot Mijn BSL.

» Andere revante producten voor Erasmus MC studenten en medewerkers.

Registreer

Om ook buiten de locaties van Erasmus MC, thuis bijvoorbeeld, van Mijn BSL gebruik te kunnen maken, moet je jezelf eenmalig registreren. Dit kan alleen vanaf een computer op een van de locaties van Erasmus MC.

Eenmaal geregistreerd kun je thuis of waar ook ter wereld onbeperkt toegang krijgen tot Mijn BSL.

Login

Als u al geregistreerd bent, hoeft u alleen maar in te loggen om onbeperkt toegang te krijgen tot Mijn BSL.

Inloggen
Top
Netherlands Heart Journal
Gepubliceerd in:

01-04-2013 | ICIN

Rate control in atrial fibrillation, insight into the RACE II study

Auteurs: H. F. Groenveld, H. J. G. M. Crijns, J. G. P. Tijssen, M. Alings, H. L. Hillege, Y. S. Tuininga, M. P. Van den Berg, D. J. Van Veldhuisen, I. C. Van Gelder

Gepubliceerd in: Netherlands Heart Journal | Uitgave 4/2013

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Extract

Currently, in Europe, more than 6 million patients have atrial fibrillation (AF) [1]. It is expected that this number will double in the next 30–50 years [1‐3]. With AF, the risk of death, stroke and heart failure is increased [4‐6], and exercise capacity and quality of life are reduced [7, 8]. Thus, AF is not a benign disease. Despite efforts to maintain sinus rhythm, AF is a progressive arrhythmia [9‐11] and many patients eventually develop permanent AF. Until recently, the treatment of this specific patient group was not evidence based. An evidence-based treatment strategy is indispensable considering the large patient population. …
vorige artikel Quadricuspid pulmonary valve and left pulmonary artery aneurysm in an asymptomatic patient assessed by cardiovascular MRI
volgende artikel Palpitations in a 19-year-old man, take a second look
Literatuur
1.
Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace. 2010;12:1360–420.CrossRef
2.
Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–53.CrossRef
3.
Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA. 2001;285:2370–5.CrossRef
4.
Benjamin EJ, Wolf PA, D’Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998;98:946–52.CrossRef
5.
Jorgensen HS, Nakayama H, Reith J, et al. Acute stroke with atrial fibrillation. The Copenhagen Stroke Study. Stroke. 1996;27:1765–9.CrossRef
6.
Dries DL, Exner DV, Gersh BJ, et al. Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trials. Studies of Left Ventricular Dysfunction. J Am Coll Cardiol. 1998;32:695–703.CrossRef
7.
Dorian P, Jung W, Newman D, et al. The impairment of health-related quality of life in patients with intermittent atrial fibrillation: implications for the assessment of investigational therapy. J Am Coll Cardiol. 2000;36:1303–9.CrossRef
8.
Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation. Results from the Rate Control Versus Electrical Cardioversion (RACE) study. J Am Coll Cardiol. 2004;43:241–7.CrossRef
9.
Lown B, Amarasingham R, Neuman J. New method for terminating cardiac arrhythmias. Use of synchronized capacitor discharge. JAMA. 1962;182:548–55.CrossRef
10.
Brown KW, Whitehead EH, Morrow JD. Treatment of cardiac arrhythmias with synchronized electrical countershock. Can Med Assoc J. 1964;90:103–5.PubMedPubMedCentral
11.
McDonald L, Resnekov L, O’Brien K. Direct-current shock in treatment of drug-resistant cardiac arrhythmias. Br Med J. 1964;1:1468–70.CrossRef
12.
Hohnloser SH, Kuck KH, Lilienthal J. Rhythm or rate control in atrial fibrillation—Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet. 2000;356:1789–94.CrossRef
13.
Wyse DG, Waldo AL, DiMarco JP, et al. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med. 2002;347:1825–33.CrossRef
14.
Van Gelder IC, Hagens VE, Bosker HA, et al. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med. 2002;347:1834–40.CrossRef
15.
Carlsson J, Miketic S, Windeler J, et al. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study. J Am Coll Cardiol. 2003;41:1690–6.CrossRef
16.
Opolski G, Torbicki A, Kosior DA, et al. Rate control vs rhythm control in patients with nonvalvular persistent atrial fibrillation: the results of the Polish How to Treat Chronic Atrial Fibrillation (HOT CAFE) study. Chest. 2004;126:476–86.CrossRef
17.
Ogawa S, Yamashita T, Yamazaki T, et al. Optimal treatment strategy for patients with paroxysmal atrial fibrillation: J-RHYTHM study. Circ J. 2009;73:242–8.CrossRef
18.
Roy D, Talajic M, Nattel S, et al. Rhythm control versus rate control for atrial fibrillation and heart failure. N Engl J Med. 2008;358:2667–77.CrossRef
19.
Fuster V, Ryden LE, Cannom DS, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006;114:e257–354.CrossRef
20.
Cooper HA, Bloomfield DA, Bush DE, et al. Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] study). Am J Cardiol. 2004;93:1247–53.CrossRef
21.
Groenveld HF, Crijns HJ, Rienstra M, et al. Does intensity of rate control influence outcome in persistent atrial fibrillation? Data of the RACE study. Am Heart J. 2009;158:785–91.CrossRef
22.
Yahalom J, Klein HO, Kaplinsky E. Beta-adrenergic blockade as adjunctive oral therapy in patients with chronic atrial fibrillation. Chest. 1977;71:592–6.CrossRef
23.
David D, Segni ED, Klein HO, et al. Inefficacy of digitalis in the control of heart rate in patients with chronic atrial fibrillation: beneficial effect of an added beta adrenergic blocking agent. Am J Cardiol. 1979;44:1378–82.CrossRef
24.
Stern EH, Pitchon R, King BD, et al. Clinical use of oral verapamil in chronic and paroxysmal atrial fibrillation. Chest. 1982;81:308–11.CrossRef
25.
Lang R, Klein HO, Weiss E, et al. Superiority of oral verapamil therapy to digoxin in treatment of chronic atrial fibrillation. Chest. 1983;83:491–9.CrossRef
26.
Panidis IP, Morganroth J, Baessler C. Effectiveness and safety of oral verapamil to control exercise-induced tachycardia in patients with atrial fibrillation receiving digitalis. Am J Cardiol. 1983;52:1197–201.CrossRef
27.
DiBianco R, Morganroth J, Freitag JA, et al. Effects of nadolol on the spontaneous and exercise-provoked heart rate of patients with chronic atrial fibrillation receiving stable dosages of digoxin. Am Heart J. 1984;108:1121–7.CrossRef
28.
Myers J, Atwood JE, Sullivan M, et al. Perceived exertion and gas exchange after calcium and beta-blockade in atrial fibrillation. J Appl Physiol. 1987;63:97–104.CrossRef
29.
Atwood JE, Myers JN, Sullivan MJ, et al. Diltiazem and exercise performance in patients with chronic atrial fibrillation. Chest. 1988;93:20–5.CrossRef
30.
Koh KK, Song JH, Kwon KS, et al. Comparative study of efficacy and safety of low-dose diltiazem or betaxolol in combination with digoxin to control ventricular rate in chronic atrial fibrillation: randomized crossover study. Int J Cardiol. 1995;52:167–74.CrossRef
31.
Koh KK, Kwon KS, Park HB, et al. Efficacy and safety of digoxin alone and in combination with low-dose diltiazem or betaxolol to control ventricular rate in chronic atrial fibrillation. Am J Cardiol. 1995;75:88–90.CrossRef
32.
Atwood JE, Myers J, Quaglietti S, et al. Effect of betaxolol on the hemodynamic, gas exchange, and cardiac output response to exercise in chronic atrial fibrillation. Chest. 1999;115:1175–80.CrossRef
33.
Farshi R, Kistner D, Sarma JS, et al. Ventricular rate control in chronic atrial fibrillation during daily activity and programmed exercise: a crossover open-label study of five drug regimens. J Am Coll Cardiol. 1999;33:304–10.CrossRef
34.
Olshansky B, Rosenfeld LE, Warner AL, et al. The Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study: approaches to control rate in atrial fibrillation. J Am Coll Cardiol. 2004;43:1201–8.CrossRef
35.
Van Gelder IC, Wyse DG, Chandler ML, et al. Does intensity of rate-control influence outcome in atrial fibrillation? An analysis of pooled data from the RACE and AFFIRM studies. Europace. 2006;8:935–42.CrossRef
36.
Van Gelder IC, Van Veldhuisen DJ, Crijns HJ, et al. RAte Control Efficacy in permanent atrial fibrillation: a comparison between lenient versus strict rate control in patients with and without heart failure. Background, aims, and design of RACE II. Am Heart J. 2006;152:420–6.CrossRef
37.
Van Gelder IC, Groenveld HF, Crijns HJ, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:1363–73.CrossRef
38.
Groenveld HF, Tijssen JG, Crijns HJ, et al. Rate Control Efficacy in permanent atrial fibrillation: successful and failed strict rate control against a background of lenient rate control. Data from the RACE II study. J Am Coll Cardiol. 2013;61:741–8.CrossRef
39.
Friberg L, Rosenqvist M. Cardiovascular hospitalization as a surrogate endpoint for mortality in studies of atrial fibrillation: report from the Stockholm Cohort Study of Atrial Fibrillation. Europace. 2011;13:626–33.CrossRef
40.
Nieuwlaat R. The value of cardiovascular hospitalization as an endpoint for clinical atrial fibrillation research. Europace. 2011;13:601–2.CrossRef
41.
Lechat P, Hulot JS, Escolano S, et al. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation. 2001;103:1428–33.CrossRef
42.
Van Veldhuisen DJ, Aass H, El Allaf D, et al. Presence and development of atrial fibrillation in chronic heart failure. Experiences from the MERIT-HF study. Eur J Heart Fail. 2006;8:539–46.CrossRef
43.
Connolly SJ, Camm AJ, Halperin JL, et al. Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med. 2011;365:2268–76.CrossRef
44.
Groenveld HF, Crijns HJ, Van den Berg MP, et al. The effect of rate control on quality of life in patients with permanent atrial fibrillation: data from the RACE II (Rate Control Efficacy in Permanent Atrial Fibrillation II) study. J Am Coll Cardiol. 2011;58:1795–803.CrossRef
Metagegevens
Titel
Rate control in atrial fibrillation, insight into the RACE II study
Auteurs
H. F. Groenveld
H. J. G. M. Crijns
J. G. P. Tijssen
M. Alings
H. L. Hillege
Y. S. Tuininga
M. P. Van den Berg
D. J. Van Veldhuisen
I. C. Van Gelder
Publicatiedatum
01-04-2013
Uitgeverij
Springer Berlin Heidelberg
Gepubliceerd in
Netherlands Heart Journal / Uitgave 4/2013
Print ISSN: 1568-5888
Elektronisch ISSN: 1876-6250
DOI
https://doi.org/10.1007/s12471-013-0391-1

Andere artikelen Uitgave 4/2013

Incidence and predictors of phantom shocks in implantable cardioverter defibrillator recipients

  • Original Article

Detrimental effects of endogenous oestrogens on primary acute myocardial infarction among postmenopausal women

  • Original Article

Crown years for noninvasive cardiovascular imaging (part I): 60 years of echocardiography

  • Open Access
  • Editor's comment

Phantom shocks: innocent bystander or complication of implantable cardioverter defibrillator therapy?

  • Editorial Comment

Palpitations in a 19-year-old man, take a second look

  • Rhythm Puzzle - Question

Quadricuspid pulmonary valve and left pulmonary artery aneurysm in an asymptomatic patient assessed by cardiovascular MRI

  • Open Access
  • Case Report